ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis — ERASE

Endocarditis Infective Clinical Trial

Official title:
An Open-Label, Multiple-Ascending Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LSVT-1701 as an Add-on to Standard of Care Antibiotics for the Treatment of Complicated Methicillin-Sensitive and -Resistant Staphylococcus Aureus Bacteremia Including Left- and Right-sided Infective Endocarditis

Status Withdrawn

Clinical Trial Summary

This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB), including left- and right-sided infective endocarditis (IE).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05329168
Study type	Interventional
Source	Lysovant
Contact
Status	Withdrawn
Phase	Phase 2
Start date	May 1, 2022
Completion date	November 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05061355` - Antibiotics vs Antibiotics and Surgical ThERapy for Infective Endocarditis	N/A
Not yet recruiting	`NCT05398679` - Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis	Phase 4
Recruiting	`NCT03211975` - Study of the Prognosis of Infectious Endocarditis (EPEI)
Recruiting	`NCT05791357` - The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis	N/A
Active, not recruiting	`NCT05037474` - Contemporary Transvenous Lead Extraction Outcomes